Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies
Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography–tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine ($ HR_{+1 SD increase} $ = 1.26; 95% CI 1.06–1.51) and 2-AAA ($ HR_{+1 SD increase} $ = 1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Cardiovascular diabetology - 18(2019), 1 vom: 13. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Razquin, Cristina [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
© The Author(s) 2019 |
|---|
| doi: |
10.1186/s12933-019-0958-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR028552725 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR028552725 | ||
| 003 | DE-627 | ||
| 005 | 20230519221223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12933-019-0958-2 |2 doi | |
| 035 | |a (DE-627)SPR028552725 | ||
| 035 | |a (SPR)s12933-019-0958-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Razquin, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2019 | ||
| 520 | |a Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography–tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine ($ HR_{+1 SD increase} $ = 1.26; 95% CI 1.06–1.51) and 2-AAA ($ HR_{+1 SD increase} $ = 1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003 | ||
| 650 | 4 | |a Biomarkers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metabolites |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiovascular disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dietary intervention |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ruiz-Canela, Miguel |4 aut | |
| 700 | 1 | |a Clish, Clary B. |4 aut | |
| 700 | 1 | |a Li, Jun |4 aut | |
| 700 | 1 | |a Toledo, Estefania |4 aut | |
| 700 | 1 | |a Dennis, Courtney |4 aut | |
| 700 | 1 | |a Liang, Liming |4 aut | |
| 700 | 1 | |a Salas-Huetos, Albert |4 aut | |
| 700 | 1 | |a Pierce, Kerry A. |4 aut | |
| 700 | 1 | |a Guasch-Ferré, Marta |4 aut | |
| 700 | 1 | |a Corella, Dolores |4 aut | |
| 700 | 1 | |a Ros, Emilio |4 aut | |
| 700 | 1 | |a Estruch, Ramon |4 aut | |
| 700 | 1 | |a Gómez-Gracia, Enrique |4 aut | |
| 700 | 1 | |a Fitó, Montse |4 aut | |
| 700 | 1 | |a Lapetra, Jose |4 aut | |
| 700 | 1 | |a Romaguera, Dora |4 aut | |
| 700 | 1 | |a Alonso-Gómez, Angel |4 aut | |
| 700 | 1 | |a Serra-Majem, Lluis |4 aut | |
| 700 | 1 | |a Salas-Salvadó, Jordi |4 aut | |
| 700 | 1 | |a Hu, Frank B. |4 aut | |
| 700 | 1 | |a Martínez-González, Miguel A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular diabetology |d London : BioMed Central, 2002 |g 18(2019), 1 vom: 13. Nov. |w (DE-627)SPR028533577 |w (DE-600)2093769-6 |x 1475-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:1 |g day:13 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12933-019-0958-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 1 |b 13 |c 11 | ||